estrogen treatment with intermittent progestin to protect the endometrium. It is estimated that a regimen of GnRHA plus add-back ultra low-dose estrogen and progestin would prevent some two-thirds of current breast cancer if used from age 30. If used from age 20 almost nine out of ten current breast cancer cases would be avoided. If, as is likely, these estimates also apply to women at high genetic risk of breast cancer because of possession of a BRCA1 or BRCA2 gene, their breast cancer risk would be reduced to below that of 'normal' women. The protective effects on ovarian cancer are calculated to be greater than the protective effects on breast cancer. Practical chemoprevention of breast and ovarian cancer using this approach should be possible within 5 years. Endocrine-Related Cancer (1997) 4 [125] [126] [127] [128] [129] [130] [131] [132] [133] Surgical menopause and breast cancer risk Epidemiological studies have found that breast cancer risk decreases with decreasing age at meno¬ pause (Table 1) (Lilienfeld 1956 , Hirayama & Wynder 1962 , Feinleib 1968 , Trichopoulos et al. 1972 , Kelsey 1979 . This is the key epidemiological observation on the relationship of ovarian hormones to breast cancer risk. Most importantly, surgical menopause (bilateral oophorectomy) has an effect which is at least as large as that associated with natural menopause (Table 1) . Hirayama & Wynder ( 1962) found a 59% reduction in breast cancer risk in women who had a surgical menopause before age 37 in their case-control study. Feinleib (1968) noted in his cohort study that women with surgical meno¬ pause before age 40 had a 75% reduction in breast cancer risk, and in the case-control study of Trichopoulos etal. (1972) surgical menopause below age 35 was associated with a 64% reduction in breast cancer risk. The findings are very consistent and there is a large decrease in breast cancer risk with early bilateral oophorectomy. The situation is illus¬ trated in Fig. 1 which shows the age-incidence curve of breast cancer for 'normal' women with meno¬ pause around age 50 and the age incidence for women with bilateral oophorectomy at age 35. (Spicer et al. 1993 (Spicer et al. , 1994 .
Add-back estrogen/progestin
The regimen we used in our GEP pilot trial is shown in The predicted effect on breast cancer risk of using the GEP regimen for a limited length of time and then stopping is illustrated in Fig. 4 for 10 years of use from age 30 to 40. Essentially the slopes of the incidence curve are as shown in Fig. 3 Table 4 is that this use of the regimen all occurs before the perimenopausal period with its associated declining levels of ovarian estrogen and progesterone.
GEP pilot study
We have tested the prototype GEP regimen (Table 3) in a pilot clinical trial (Spicer et al. 1993 (Spicer et al. , 1994 In an editorial accompanying the report (Spicer et al. 1994 ) of the effect of the GEP regimen on mammographie densities, Feig (1994) suggested that finding early cancers in mammograms from women on such a regimen would be much easier than in 'normal' premenopausal women. This could lead to a greatly improved efficacy of screening mammog¬ raphy in young women. (Pike 1987 (Pike 1987 Laidlaw et al. (1995) and by Cline etal. (1996) . Laidlaw et al. (1995) implanted normal human breast tissue into athymic nude mice and found that cell proliferation was proportional to estradiol dose up to a dose of a 2 mg pellet, but a further increase to a 6 mg pellet had no additional effect. When a progesterone pellet was added to the maximally effective dose of estradiol (i.e. the 2 mg pellet) no further increase in cell proliferation was noted. This was interpreted in the paper as implying that 'proges¬ terone does not affect proliferation'. The results, however, only support the much weaker statement that 'the addition of progesterone to a maximally stimulatory dose of estradiol does not further increase cell proliferation' (Pike et al. 1996) . Cline et al. (1996) 
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